Oxycodone: Strong Opioid Analgesic for Severe Pain Management
Oxycodone is a semi-synthetic opioid analgesic derived from thebaine, an alkaloid of the opium poppy. It is classified as a strong opioid and acts primarily as a mu-opioid receptor (MOR) agonist. In Germany and most European countries, oxycodone is subject to narcotic prescription requirements (Betäubungsmittelrezept, BtM), reflecting its potential for dependence and misuse. It is used in the management of moderate-to-severe pain, particularly cancer pain and severe chronic pain, where simpler analgesic options are insufficient.
Oxycodone is available in several formulations: immediate-release for acute breakthrough pain and controlled-release (retard) tablets for round-the-clock baseline pain management. A notable fixed-dose combination product, oxycodone/naloxone (marketed as Targin), is specifically designed to address one of the most problematic side effects of opioid therapy: opioid-induced constipation. Naloxone in this combination antagonizes opioid receptors locally in the gastrointestinal tract (it is extensively metabolized in the liver after absorption and has negligible systemic opioid-antagonist effects at recommended doses), thereby reducing constipation without compromising systemic analgesia.
Mechanism of Action
Oxycodone exerts its analgesic effects primarily through agonism at mu-opioid receptors (MOR), which are G-protein-coupled receptors (GPCRs) widely distributed in the CNS and peripheral nervous system. MOR activation in the brain and spinal cord modulates pain transmission through multiple mechanisms: inhibition of adenylyl cyclase (reducing cAMP), opening of potassium channels (leading to membrane hyperpolarization and reduced neuronal excitability), and inhibition of voltage-gated calcium channels (reducing neurotransmitter release from pain-transmitting neurons). At the level of the spinal dorsal horn, opioids inhibit the release of excitatory neurotransmitters from primary afferent pain fibers and reduce the responsiveness of dorsal horn neurons to nociceptive input. At the supraspinal level, opioids activate descending inhibitory pathways that project from the periaqueductal gray matter to the spinal cord, further suppressing pain signaling. Oxycodone may also activate kappa-opioid receptors, contributing to visceral analgesia. The combination of these central mechanisms produces powerful analgesia for both somatic and visceral pain. Beyond analgesia, MOR agonism mediates the other effects of oxycodone including euphoria (via mesolimbic reward pathways), respiratory depression (via medullary respiratory centers), sedation, constipation (via peripheral enteric MOR), and antitussive activity. Oxycodone is metabolized primarily by CYP3A4 to noroxycodone (the main metabolite, with modest activity) and by CYP2D6 to oxymorphone (a potent MOR agonist that contributes to some of the clinical effects in extensive metabolizers).
Indications
Oxycodone is indicated for the treatment of severe pain that requires an around-the-clock, long-term opioid analgesic and for which alternative treatments are inadequate. In cancer pain management, oxycodone is a first-line strong opioid following the WHO analgesic ladder approach, where it is initiated when weak opioids (tramadol, codeine) combined with non-opioid analgesics no longer provide adequate pain control. It is effective for both nociceptive and, to some extent, neuropathic components of cancer pain. In chronic non-cancer pain, oxycodone may be prescribed for severe refractory pain conditions such as severe osteoarthritis, neuropathic pain syndromes, and post-herpetic neuralgia when non-opioid and weak opioid approaches have been exhausted and after careful assessment of the benefit-risk balance and potential for misuse. Post-operative pain management can use immediate-release oxycodone for moderate-to-severe acute surgical pain, typically as part of a multimodal analgesic approach. The oxycodone/naloxone combination (Targin) is indicated for severe pain requiring regular long-term opioid treatment where opioid-induced constipation is a significant clinical problem, providing equivalent analgesia to oxycodone alone with meaningfully improved bowel function.
Dosage and Administration
Oxycodone dosing is highly individualized and must be carefully titrated to the patient's pain and tolerance. For opioid-naive adults, controlled-release (CR) oxycodone is typically started at 10 mg every 12 hours, with immediate-release (IR) oxycodone (5 mg) available as breakthrough analgesia (typically one-sixth of the total daily CR dose per breakthrough dose, not to exceed once every 4 hours). The dose is titrated upward every 1 to 2 days based on breakthrough dose usage and pain scores until adequate analgesia is achieved. There is no predefined maximum dose for cancer pain, though titration requires monitoring for adverse effects; many patients achieve adequate cancer pain control with 60 to 200 mg daily. For non-cancer pain, doses are generally kept as low as effective and regularly reassessed. Controlled-release tablets must be swallowed whole and must never be crushed, broken, or chewed, as this destroys the extended-release mechanism and leads to rapid release of a potentially fatal dose. In renal and hepatic impairment, dose reduction and increased dosing intervals are required. In elderly patients, initial doses should be reduced and titration performed more cautiously.
Side Effects
Opioid-induced constipation is the most universal and persistent adverse effect of oxycodone and all opioids. Unlike most other opioid side effects, constipation does not diminish with chronic use (no tolerance develops). All patients starting regular opioid therapy should receive a prophylactic stimulant laxative (e.g., sodium picosulfate or bisacodyl, or macrogol for softening). The oxycodone/naloxone combination reduces constipation significantly. Nausea and vomiting are common at initiation and typically subside within the first weeks as tolerance develops; antiemetics should be available at treatment initiation. Sedation and cognitive impairment occur, particularly at the start of treatment or after dose increases, and are usually transient as tolerance develops. Respiratory depression is the most serious and potentially life-threatening adverse effect of opioids; it results from direct depression of medullary respiratory centers and is dose-dependent. Risk is higher in opioid-naive patients, in those with concurrent respiratory disease, and when opioids are combined with other CNS depressants. Pruritus (itching without rash) is a common opioid effect mediated by CNS opioid receptors. Physical dependence develops with regular opioid use; abrupt discontinuation leads to withdrawal symptoms, and doses must be tapered when discontinuing. Opioid-induced hyperalgesia (paradoxical increase in pain sensitivity with long-term high-dose opioid therapy) can complicate management in some patients. Hypogonadism, immune suppression, and endocrine effects may occur with long-term use.
Interactions
The most dangerous interaction is with other CNS depressants, including benzodiazepines, other opioids, alcohol, sedating antihistamines, antipsychotics, and general anesthetics. Co-administration of oxycodone with benzodiazepines is associated with significantly increased risk of fatal overdose due to synergistic respiratory depression; this combination carries a black box warning and should be avoided unless no alternative exists, with careful monitoring. CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, grapefruit juice) increase oxycodone plasma concentrations, potentially to toxic levels, by reducing its metabolism. CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) reduce oxycodone concentrations and may cause loss of analgesic efficacy. CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) reduce the conversion of oxycodone to oxymorphone; the clinical impact varies by patient genotype and dose. Serotonergic drugs including SSRIs, SNRIs, tricyclics, MAOIs, and serotonin agonists (triptans) may contribute to serotonin syndrome when combined with opioids, particularly in high doses. Opioid antagonists such as naltrexone or naloxone (systemic dosing) will precipitate acute withdrawal in opioid-dependent patients.
Special Notes
Oxycodone is a Schedule II controlled substance in many countries (Betäubungsmittel in Germany) and requires a special narcotic prescription. Prescribers must be familiar with applicable narcotic regulations. Thorough patient assessment including pain etiology, opioid history, and risk factors for misuse and dependence should precede initiation. Risk tools for opioid misuse screening are available and recommended, particularly for chronic non-cancer pain management. Regular reassessment of pain, function, and side effects is essential. Oxycodone extended-release formulations must be specifically prescribed and dispensed; immediate-release formulations should not be used as substitutes for extended-release without explicit prescription. Controlled-release tablets must never be crushed or dissolved, as this releases the full intended 12-hour dose instantly, creating a potentially fatal rapid bolus. In cases of opioid overdose (respiratory depression, pinpoint pupils, loss of consciousness), the antidote naloxone must be administered immediately by intravenous, intramuscular, or intranasal route by trained personnel or emergency services.
Related Topics
Frequently Asked Questions
Why must oxycodone controlled-release tablets never be crushed?
Controlled-release oxycodone tablets are engineered with a special matrix or film system designed to slowly dissolve and release the drug over 12 hours, providing stable plasma oxycodone concentrations throughout the dosing interval. If the tablet is crushed, chewed, or dissolved, the controlled-release mechanism is entirely destroyed, releasing the full intended 12-hour dose of oxycodone instantaneously. This creates a massive, rapid peak in plasma oxycodone levels, producing severe respiratory depression, loss of consciousness, and a high risk of fatal overdose. For this reason, all patients receiving oxycodone CR formulations must be explicitly instructed never to crush, break, or chew these tablets. Additionally, some CR oxycodone formulations incorporate abuse-deterrent technologies that make crushing or dissolution more difficult, though determined misuse can still circumvent these measures.
How does oxycodone/naloxone (Targin) reduce constipation without reducing pain relief?
The combination tablet contains oxycodone for systemic analgesia and naloxone to counteract opioid-induced constipation locally within the gastrointestinal tract. After oral ingestion, naloxone is absorbed in the gut where it blocks peripheral mu-opioid receptors in the enteric nervous system, preventing the opioid-mediated reduction in gastrointestinal motility and secretion that causes constipation. However, naloxone undergoes extensive first-pass metabolism in the liver, with bioavailability of less than 2 percent when given orally at standard doses. This means that virtually no naloxone reaches the systemic circulation to antagonize central opioid receptors responsible for analgesia. The result is local opioid antagonism in the gut (improving bowel function) without compromising centrally mediated analgesia. Clinical trials have demonstrated significantly better bowel function with oxycodone/naloxone compared to oxycodone alone, with equivalent pain control.
What is opioid-induced hyperalgesia?
Opioid-induced hyperalgesia (OIH) is a paradoxical state in which prolonged exposure to opioids leads to increased sensitivity to pain rather than continued analgesia. Patients with OIH experience worsening pain despite increasing opioid doses, and their pain may spread beyond the original pain site. The mechanism involves sensitization of central pain pathways including activation of NMDA receptors, upregulation of pro-nociceptive systems, and neuroplastic changes in pain processing. OIH is most commonly observed with high-dose, long-term opioid therapy and can be difficult to distinguish from tolerance (reduced analgesia requiring dose increase) or disease progression. Management may involve opioid dose reduction or rotation to a different opioid, addition of NMDA receptor antagonists such as ketamine, or multidisciplinary pain management approaches. Recognition of OIH is clinically important because the counterintuitive response to increasing opioid doses in this setting may worsen rather than improve the patient's condition.
Sources
- WHO: Cancer Pain Relief with a Guide to Opioid Availability. 2nd ed. World Health Organization. 1996.
- Caraceni A et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012.
- EMA: Oxycodone/naloxone (Targin) Summary of Product Characteristics, current version.